natgillin/translations-raw huggingface dataset:
Death due to PAH as a component of the endpoint was observed in 16 (2.8%) patients on selexipag and 14 (2.4%) on placebo.
Smrt zbog PAH-a kao komponenta mjere ishoda zabilježena je u 16 (2,8%) bolesnika koji su primali seleksipag i 14 (2,4%) bolesnika koji su primali placebo.
The glucuronidation of the active metabolite is catalysed by UGT1A3 and UGT2B7.
Glukuronidaciju aktivnog metabolita kataliziraju UGT1A3 i UGT2B7.
If it is within 6 hours of when you would normally take your next dose, you should skip the missed dose and continue to take your medicine at the usual time.
Ako ima manje od 6 sati do vremena kad biste obično uzeli sljedeću dozu, trebate preskočiti zaboravljenu dozu i nastaviti uzimati svoj lijek u uobičajeno vrijeme.
Selexipag is rapidly absorbed and is hydrolysed by carboxylesterases to its active metabolite.
Apsorpcija Seleksipag se brzo apsorbira i hidrolizira putem karboksilesteraza u svoj aktivni metabolit.
Your doctor or nurse can prescribe an equivalent single-tablet strength for your maintenance dose.
Vaš Vam liječnik ili medicinska sestra može propisati odgovarajuću jačinu u jednoj tableti za dozu održavanja.
The patients will receive an identical titration guide and Patient Leaflet in their titration packs of Uptravi.
Isti takav vodič za titraciju i uputu o lijeku bolesnici će dobiti u svom pakiranju za titraciju doze
If it is nearly time for your next dose (within 6 hours before you would normally take it), you should skip the missed dose and continue to take your medicine at the usual time.
Ako je uskoro vrijeme za Vašu sljedeću dozu (manje od 6 sati do redovnog uzimanja) preskočite zaboravljenu dozu i nastavite uzimati svoj lijek u uobičajeno vrijeme.
Page 8
Stranica 8
Patients were randomised to either placebo (N = 582) or selexipag (N = 574) twice daily.
Bolesnici su bili randomizirani kako bi primali placebo (N = 582) ili seleksipag
If the therapy is not tolerated at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered.
Ako bolesnik ne podnosi terapiju u danoj dozi, treba razmotriti liječenje simptoma i/ili smanjenje doze na sljedeću nižu dozu.
In the presence of 600 mg rifampicin, once a day, an inducer of CYP2C8 (and UGT enzymes), the exposure to selexipag did not change, whereas exposure to the active metabolite was reduced by half.
U prisutnosti 600 mg rifampicina, jedanput dnevno, induktora CYP2C8 (i UGT enzima), izloženost seleksipagu nije se promijenila, dok se izloženost aktivnom metabolitu smanjila za pola.
There is limited experience with abrupt discontinuation of Uptravi in patients with PAH.
Iskustvo s naglim prekidanjem uzimanja Uptravija u bolesnika s PAH-om je ograničeno.
In the Phase 3 placebo-controlled study in patients with PAH, a transient increase in mean heart rate of 3-4 bpm at 2-4 hours post-dose was observed.
U placebom kontroliranom ispitivanju faze 3 u bolesnika s PAH-om uočen je prolazan porast srednje vrijednosti frekvencije srca od 3-4 otkucaja/minuti 2-4 sata poslije uzimanja doze.
Dosage Adjustment with Co-administration of Moderate CYP2C8 Inhibitors
Prilagodba doze uz istodobnu primjenu umjerenih inhibitora CYP2C8
Talk to your PAH doctor or nurse if you are taking any of the following medicines: - Gemfibrozil (medicine used to lower the level of fats [lipids] in the blood) - Clopidogrel (medicine used to inhibit blood clots in coronary artery disease) - Deferasirox (medicine used to remove iron from the blood stream) - Teriflunomide (medicine used to treat relapsing-remitting multiple sclerosis) - Carbamazepine (medicine used to treat some forms of epilepsy, nerve pain or to help control serious mood disorders when some other medicines do not work) - Phenytoin (medicine used to treat epilepsy) - Valproic acid (medicine used to treat epilepsy) - Probenecid (medicine used to treat gout) - Fluconazole, rifampicin or rifapentine (antibiotics used to treat infections)
- Teriflunomid (lijek koji se primjenjuje za liječenje relapsno-remitirajuće multiple skleroze) - Karbamazepin (lijek koji se primjenjuje za liječenje nekih oblika epilepsije, bol u živčanom sustavu ili za kontrolu ozbiljnih poremećaja raspoloženja kada neki drugi lijekovi ne djeluju) - Fenitoin (lijek koji se primjenjuje za liječenje epilepsije) - Valproatnu kiselinu (lijek koji se primjenjuje za liječenje epilepsije) - Probenecid (lijek koji se primjenjuje za liječenje gihta) - Flukonazol, rifampicin ili rifapentin (antibiotici koji se koriste za liječenje infekcija)
Your doctor may step you down to a lower dose.
Vaš liječnik može Vam smanjiti dozu.
The active metabolite is a weak substrate of the breast cancer resistance protein (BCRP).
Aktivni metabolit je slabi supstrat za protein koji uzrokuje rezistenciju raka dojke na lijekove
Treatment with selexipag resulted in a placebo-corrected median effect on 6MWD measured at trough (i.e., approximately 12 h post-dose) of 12 m at Week 26 (99% CI: 1, 24 m;
Liječenje seleksipagom dovelo je do učinka na vrijednost medijana 6MTH korigiranu u odnosu na placebo, mjerenu na kraju doznog intervala (npr. približno 12 sati nakon uzimanja doze) za 12 m u 26. tjednu (99% CI: 1, 24 m; jednostrana p-vrijednost = 0,0027).
Page 30
Stranica 30
CI = confidence interval; EOT = end of treatment; HR = hazard ratio; i.v.
CI = interval pouzdanosti; EOT = završetak liječenja (od engl. end of treatment); HR = omjer hazarda; i.v. = intravenski; PAH = plućna arterijska hipertenzija; s.c. = supkutano.
More subjects reported adverse events after administration in the fasted than in the fed state.
Više ispitanika prijavilo je nuspojave nakon uzimanja lijeka natašte nego nakon uzimanja u sitom stanju.
If the therapy over time is less tolerated at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered.
Ako se liječenje tijekom vremena slabije podnosi pri danoj dozi, treba razmotriti simptomatsko liječenje i/ili smanjenje doze na prethodnu manju dozu.
Selexipag and its main metabolite showed 20- to 80-times lower prostacyclin (IP) receptor potency in vitro for animal species used in reproductive toxicity testing compared to humans.
do 80 puta manju potentnost prostaciklinskih (IP) receptora u životinjskih vrsta na kojima je ispitana reproduktivna toksičnost u usporedbi s ljudima.
Page 38
Stranica 38
The number of deaths due to PAH up to study closure was 70 (12.2%) for the selexipag group and 83 (14.3%) for the placebo group.
Broj smrtnih slučajeva zbog PAH-a do završetka ispitivanja bio je 70 (12,2%) u skupini koja je primala seleksipag i 83 (14,3%) u skupini koja je primala placebo.
During titration, you may experience side effects such as headache, diarrhoea, feeling sick (nausea), being sick (vomiting), jaw pain, muscle pain, leg pain, joint pain, or reddening of the face (see section 4).
Tijekom titracije doze, mogu Vam se javiti nuspojave kao što su glavobolja, proljev, mučnina, povraćanje, bol u čeljusti, bol u mišićima, bol u nogama, bol u zglobovima ili crvenilo lica (pogledajte dio 4.).
If you miss a dose, take the dose as soon as you remember, then continue to take your tablets at the usual times.
Ako zaboravite uzeti dozu, uzmite ju čim se sjetite, a potom nastavite uzimati svoje tablete u uobičajeno vrijeme.
In the presence of 600 mg gemfibrozil, twice a day, a strong inhibitor of CYP2C8, exposure to selexipag increased approximately 2-fold, whereas exposure to the active metabolite, the major contributor to efficacy, increased approximately 11-fold.
U prisutnosti 600 mg gemfibrozila, dva puta dnevno, jakog inhibitora CYP2C8, izloženost seleksipagu povećala se približno dvostruko, dok se izloženost aktivnom metabolitu, koji ima glavni doprinos djelotvornosti, povećala približno 11 puta.
Page 35
Stranica 35
Thyroid function tests are recommended as clinically indicated in the presence of signs or symptoms of hyperthyroidism.
U slučaju pojave znakova ili simptoma hipertireoze preporučuje se učiniti testove funkcije štitnjače prema kliničkim indikacijama.
No change in starting dose is required in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2); dose titration should be done with caution in these patients (see section 4.4).
(procijenjena brzina glomerularne filtracije [eGFR] < 30 ml/min/1,73 m2); titraciju doze u ovih bolesnika treba provoditi oprezno (vidjeti dio 4.4).
Uptravi is used for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients insufficiently controlled with other types of medicines for PAH known as endothelin receptor antagonists and phosphodiesterase type 5 inhibitors.
Uptravi se primjenjuje za dugotrajno liječenje plućne arterijske hipertenzije (PAH-a) u odraslih bolesnika u kojih bolest nije dovoljno kontrolirana drugim vrstama lijekova za PAH poznatih kao antagonisti endotelinskih receptora i inhibitori fosfodiesteraze tipa 5. Uptravi se može primjenjivati i sam u bolesnika koji nisu pogodni za liječenje ovim lijekovima.
Median 6MWD at baseline was 376 m (range: 90-482 m) and 369 m (range: 50-515 m) in selexipag patients and placebo patients, respectively.
Medijan 6MTH na početku ispitivanja bio je 376 m (raspon: 90-482 m) u bolesnika koji su primali seleksipag odnosno 369 m
Each patient should be up-titrated to the highest individually tolerated dose, which can range from 200 micrograms given twice daily to 1,600 micrograms given twice daily (individualised maintenance dose).
Individualizirana titracija doze Svakom bolesniku treba polako povećavati dozu do najveće doze koju može podnositi, što može biti u rasponu od 200 mikrograma uzeto dva puta dnevno do 1600 mikrograma uzeto dva puta dnevno (individualizirana doza održavanja).
Abdominal pain
bol u abdomenu
• Lay language version of the healthcare professional A4 laminated titration guide;
• Inačicu vodiča za titraciju doze za zdravstvenog radnika na plastificiranom kartonu A4 formata pisanu laičkim jezikom;
In a thorough QT study in healthy subjects, repeated doses of 800 and 1,600 micrograms of selexipag twice daily did not show an effect on cardiac repolarisation (QTc interval) or conduction (PR and QRS intervals) and had a mild accelerating effect on heart rate (the placebo-corrected, baseline-adjusted increase in heart rate reached 6-7 bpm at 1.5 to 3 h after dosing with 800 micrograms selexipag and 9-10 bpm at the same timepoints after 1,600 micrograms selexipag).
U ispitivanju QT intervala na zdravim ispitanicima, ponovljene doze od 800 i 1600 mikrograma seleksipaga dva puta dnevno nisu pokazale učinak na repolarizaciju srca (QTc interval) ili provođenje (PR i QRS intervali), a imale su blagi utjecaj na povećanje frekvencije srca (porast frekvencije, korigiran u odnosu na placebo i prilagođen početnim vrijednostima, dosegao je 6-7 otkucaja/minuti
Disease progression b n (%)
Progresija bolesti b n (%) i.v./s.c.
Page 25
Stranica 25
The dose was increased at weekly intervals by increments of 200 micrograms given twice daily to determine the individualised maintenance dose (200-1,600 micrograms twice daily).
200 mikrograma davan dva puta dnevno kako bi se odredila individualizirana doza održavanja (200-1600 mikrograma dva puta dnevno).
Dosing frequency of Uptravi should be reverted to twice daily when co-administration of moderate CYP2C8 inhibitor is stopped (see section 4.2).
Učestalost doziranja lijeka Uptravi treba vratiti na dvaput dnevno nakon prekida istodobne primjene umjerenog inhibitora CYP2C8 (vidjeti dio 4.2).
Page 31
Stranica 31
Page 20
Stranica 20
Treatment comparison: selexipag vs placebo
Bolesnici s događajem Usporedba liječenja: seleksipag u odnosu na placebo
Page 23
Stranica 23
Page 5
Stranica 5
• Healthcare professional A4 laminated titration guide;
• Vodič za titraciju doze za zdravstvenog radnika na plastificiranom kartonu A4 formata; • Vodič za titraciju doze za bolesnika;
During dose titration some adverse reactions, reflecting the mode of action of Uptravi (such as headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing), may occur.
Tijekom titracije doze mogu se javiti neke nuspojave zbog načina djelovanja Uptravija (kao što su glavobolja, proljev, mučnina i povraćanje, bol u čeljusti, mialgija, bol u ekstremitetima, artralgija i crvenilo uz osjećaj vrućine).
Page 33
Stranica 33
Page 16
Stranica 16
Uptravi film-coated tablets selexipag
Uptravi filmom obložene tablete seleksipag
Page 39
Stranica 39
Revert to twice daily dosing frequency of Uptravi when co-administration of moderate CYP2C8 inhibitor is stopped (see section 4.5).
Primjenu lijeka Uptravi vratite na dvaput dnevno nakon prekida istodobne primjene umjerenog inhibitora CYP2C8 (vidjeti dio 4.5).
Page 24
Stranica 24
Page 37
Stranica 37
Page 2
Stranica 2
Page 15
Stranica 15
Page 40
Stranica 40
Page 11
Stranica 11
Page 27
Stranica 27
Read the package leaflet and titration guide before use.
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije uporabe pročitajte uputu o lijeku i vodič za titraciju.
Page 28
Stranica 28
Each film-coated tablet contains 200 micrograms of selexipag
Svaka filmom obložena tableta sadrži 200 mikrograma seleksipaga
Page 9
Stranica 9
Page 32
Stranica 32
Page 36
Stranica 36
Maximum observed plasma concentrations of selexipag and its active metabolite after oral administration are reached within 1-3 h and 3-4 h, respectively.
Najveće uočene koncentracije seleksipaga i njegovog aktivnog metabolita u plazmi nakon peroralne primjene bile su dosegnute unutar 1-3 sata za seleksipag odnosno 3-4 sata za njegov aktivni metabolit.
Page 17
Stranica 17
Page 18
Stranica 18
Page 34
Stranica 34
Page 29
Stranica 29
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong CYP3A4 inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
Pri primjeni 400/100 mg lopinavira/ritonavira, jakog inhibitora CYP3A4, dva puta dnevno, izloženost seleksipagu povećala se približno dvostruko, dok se izloženost aktivnom metabolitu seleksipaga nije mijenjala.
Page 12
Stranica 12
Concomitant administration of Uptravi with strong inhibitors of CYP2C8 (e.g., gemfibrozil) is contraindicated (see section 4.3).
CYP2C8 (npr. gemfibrozil) je kontraindicirana (vidjeti dio 4.3).
The numerical increase in deaths up to end of treatment + 7 days but not up to study closure was further investigated by mathematical modelling, showing that the imbalance in deaths is consistent with the assumption of a neutral effect on PAH mortality and reduction of non-fatal events.
dalje je ispitivan matematičkim modeliranjem te se pokazalo da je nesklad u smrtnim ishodima u skladu s pretpostavkom izostanka utjecaja na mortalitet od PAH-a i smanjenjem učestalosti događaja koji nemaju smrtni ishod.
In Phase 1 and 2 studies a slight decrease in plasma levels of von Willebrand factor (vWF) was observed with selexipag; the vWF values remained above the lower limit of the normal range.
(VWF) u plazmi; vrijednosti VWF zadržale su se iznad donje granice normalnog raspona.
Page 21
Stranica 21
Page 19
Stranica 19
Page 22
Stranica 22
Page 7
Stranica 7
Page 10
Stranica 10
Page 13
Stranica 13
Uncommon side effects (may affect up to 1 in 100 people) - Increased heart rate
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) - glavobolja
Exposure to selexipag and the active metabolite at steady state in PAH patients and healthy subjects was similar.
Izloženost seleksipagu i aktivnom metabolitu u stanju dinamičke ravnoteže bila je slična u bolesnika s
Page 4
Stranica 4
Pulmonary haemodynamics
Plućna hemodinamika
The most commonly reported adverse reactions are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing.
Najčešće zabilježene nuspojave su glavobolja, proljev, mučnina i povraćanje, bol u čeljusti, mialgija,
Page 26
Stranica 26
Selexipag is hydrolysed to its active metabolite in the liver and in the intestine by carboxylesterases.
Seleksipag se hidrolizira u jetri i crijevima putem karboksilesteraza u aktivni metabolit.
Talk to your doctor or nurse if you have side effects.
Obratite se svom liječniku za PAH ili medicinskoj sestri prije nego uzmete Uptravi ako
Page 3
Stranica 3
Cases of pulmonary oedema have been reported with vasodilators (mainly prostacyclins) when used in patients with pulmonary veno-occlusive disease.
Pri primjeni vazodilatatora (uglavnom prostaciklina) u bolesnika s plućnom venookluzivnom bolesti prijavljeni su slučajevi plućnog edema.
Efficacy in patients with PAH
Lijekovi za PAH
Uptravi 200 microgram Uptravi 400 microgram Uptravi 600 microgram Uptravi 800 microgram Uptravi 1,000 microgram Uptravi 1,200 microgram Uptravi 1,400 microgram Uptravi 1,600 microgram
Uptravi 600 mikrograma Uptravi 800 mikrograma Uptravi 1000 mikrograma Uptravi 1200 mikrograma Uptravi 1400 mikrograma Uptravi 1600 mikrograma
Page 6
Stranica 6
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.
Organisation functional class), ili kao dio kombiniranog liječenja u bolesnika u kojih bolest nije dovoljno kontrolirana antagonistom endotelinskih receptora (ERA-om, engl. endothelin receptor antagonist) i/ili inhibitorom fosfodiesteraze tipa 5 (PDE-5), ili kao monoterapija u bolesnika koji nisu pogodni za prethodno navedene terapije.
At baseline, the majority of enrolled patients (80%) were being treated with a stable dose of a specific therapy for PAH, either an ERA (15%) or a PDE-5 inhibitor (32%) or both an ERA and a PDE-5 inhibitor (33%).
ERA-ima (15%) ili inhibitorima PDE-5 (32%) ili kombinacijom ERA-a i inhibitora PDE-5 (33%).
Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film-coated tablets Cartons of 60 film-coated tablets.
Uptravi 400 mikrograma, 600 mikrograma, 800 mikrograma, 1000 mikrograma, 1200 mikrograma, 1400 mikrograma, i 1600 mikrograma filmom obložene tablete Kutije sa 60 filmom obloženih tableta.
Sinus tachycardia
Srčani poremećaji sinusna tahikardija
Each film-coated tablet contains 200 micrograms of selexipag Each film-coated tablet contains 400 micrograms of selexipag Each film-coated tablet contains 600 micrograms of selexipag Each film-coated tablet contains 800 micrograms of selexipag Each film-coated tablet contains 1,000 micrograms of selexipag Each film-coated tablet contains 1,200 micrograms of selexipag Each film-coated tablet contains 1,400 micrograms of selexipag Each film-coated tablet contains 1,600 micrograms of selexipag
Svaka filmom obložena tableta sadrži 200 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 400 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 600 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 800 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 1000 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 1200 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 1400 mikrograma seleksipaga Svaka filmom obložena tableta sadrži 1600 mikrograma seleksipaga
Anaemia Haemoglobin decreased
Smanjena razina hemoglobina
Blood and lymphatic disorders
Poremećaji krvi i limfnog sustava anemija smanjena razina hemoglobina
Midazolam At steady state after up-titration to 1,600 μg selexipag twice a day, no clinically relevant change in exposure to midazolam, a sensitive intestinal and hepatic CYP3A4 substrate, or its metabolite, 1-hydroxymidazolam, was observed.
U stanju dinamičke ravnoteže nakon postupnog povećavanja doze seleksipaga do 1600 μg dvaput dnevno, nisu opažene klinički značajne promjene u izloženosti midazolamu, osjetljivom supstratu za
Uptravi 200 microgram film-coated tablets contain 200 micrograms of selexipag Uptravi 400 microgram film-coated tablets contain 400 micrograms of selexipag Uptravi 600 microgram film-coated tablets contain 600 micrograms of selexipag Uptravi 800 microgram film-coated tablets contain 800 micrograms of selexipag Uptravi 1,000 microgram film-coated tablets contain 1,000 micrograms of selexipag Uptravi 1,200 microgram film-coated tablets contain 1,200 micrograms of selexipag Uptravi 1,400 microgram film-coated tablets contain 1,400 micrograms of selexipag Uptravi 1,600 microgram film-coated tablets contain 1,600 micrograms of selexipag
Uptravi 200 mikrograma filmom obložene tablete sadrže 200 mikrograma seleksipaga Uptravi 400 mikrograma filmom obložene tablete sadrže 400 mikrograma seleksipaga Uptravi 600 mikrograma filmom obložene tablete sadrže 600 mikrograma seleksipaga Uptravi 800 mikrograma filmom obložene tablete sadrže 800 mikrograma seleksipaga Uptravi 1000 mikrograma filmom obložene tablete sadrže 1000 mikrograma seleksipaga Uptravi 1200 mikrograma filmom obložene tablete sadrže 1200 mikrograma seleksipaga Uptravi 1400 mikrograma filmom obložene tablete sadrže 1400 mikrograma seleksipaga Uptravi 1600 mikrograma filmom obložene tablete sadrže 1600 mikrograma seleksipaga
- If you have any side effects, talk to your doctor or nurse.
Ako Vam se jave nuspojave obratite se svom liječniku ili medicinskoj sestri.
Stepping down to a lower dose due to side effects
Smanjenje doze zbog nuspojava
• Headache • Diarrhoea • Nausea • Vomiting • Jaw pain • Muscle pain • Leg pain • Joint pain • Facial redness
• glavobolja • proljev • mučnina • povraćanje
Use the following diary pages if your doctor or nurse prescribes 800 microgram tablets in addition to your 200 microgram tablets.
Sljedeće stranice dnevnika koristite ako Vam Vaš liječnik ili medicinska sestra propiše tablete od
Round, light-violet, film-coated tablets with “6” debossed on one side.
Okrugle, svijetlo ljubičaste, filmom obložene tablete s utisnutim “6” na jednoj strani.
Respiratory, thoracic and mediastinal disorders
Poremećaji dišnog sustava, prsišta i sredoprsja nazofaringitis (neinfektivnog porijekla)
Elimination of selexipag is predominantly via metabolism with a mean terminal half-life of 0.8-2.5 h. The active metabolite has a half-life of 6.2-13.5 h. The total body clearance of selexipag is 17.9 L/h.
Eliminacija seleksipaga se uglavnom odvija putem metabolizma sa srednjom vrijednošću terminalnog poluživota 0,8-2,5 sati.
How to store Uptravi
Moguće nuspojave Kako čuvati Uptravi
A 1.4- to 1.7-fold increase in exposure (maximum plasma concentration and area under the plasma concentration-time curve) to selexipag and its active metabolite was observed in subjects with severe renal impairment (eGFR < 30 mL/min/1.73 m2).
U ispitanika s teškim oštećenjem funkcije bubrega (eGFR < 30 ml/min/1,73 m2) uočen je porast izloženosti (najveća koncentracija u plazmi i površina ispod krivulje koncentracije u vremenu)
PAH-specific therapy.
PAH-om i zdravih ispitanika.
doctor or nurse regularly during titration.
Sjetite se redovito razgovarati sa svojim liječnikom za PAH ili medicinskom sestrom tijekom titracije doze.
Talk to your PAH doctor or nurse before taking Uptravi if you - are taking medicines for high blood pressure - have low blood pressure associated with symptoms such as dizziness - have recently experienced significant blood loss or fluid loss such as severe diarrhoea or vomiting - have problems with your thyroid gland - have severe problems with your kidneys or are undergoing dialysis - have or have had severe problems with your liver not working properly
- ste nedavno doživjeli znatan gubitak krvi ili gubitak tekućine kao što je teški proljev ili povraćanje - imate problema sa štitnjačom
Thyroid function tests
Testovi funkcije štitnjače
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnog tkiva osip urtikarija eritem
Uptravi 800 microgram film-coated tablets Round, green, film-coated tablets with “8” debossed on one side.
Uptravi 800 mikrograma filmom obložene tablete Okrugle, zelene, filmom obložene tablete s utisnutim “8” na jednoj strani.
Uptravi 800 microgram film-coated tablets Each film-coated tablet contains 800 micrograms of selexipag.
Uptravi 800 mikrograma filmom obložene tablete Svaka filmom obložena tableta sadrži 800 mikrograma seleksipaga.